"10.1371_journal.pone.0065384","plos one","2013-06-07T00:00:00Z","Hatice Karauzum; Rajan P Adhikari; Jawad Sarwar; V Sathya Devi; Laura Abaandou; Christian Haudenschild; Mahta Mahmoudieh; Atefeh R Boroun; Hong Vu; Tam Nguyen; Kelly L Warfield; Sergey Shulenin; M Javad Aman","Integrated Biotherapeutics Inc., Gaithersburg, Maryland, United States of America","Conceived and designed the experiments: MJA HK RPA KLW SS. Performed the experiments: HK RPA JS VSD LA CH MM ARB HV. Analyzed the data: HK RPA JS VSD TN. Wrote the paper: MJA HK RPA SS.","The authors have read the journals policy and have the following conflicts: Tam Nguyen served as a consultant and all other authors were employed by Integrated Biotherapeutics, Inc. at the time work was performed. M. Javad Aman and Kelly Warfield are shareholders in the company of the Inegrated BioTherapeutics Inc., the organization at which this work was performed. Drs. Chris Clegg and Paul Sleath (Immune Design Corp.) provided GLA-SE adjuvant and NARSA repository for USA300 and NCTC8325-4 (NRS77) for this study. The authors have filed a patent application for the described mutants. This patent is not published yet but is expected to be published in July 2013. The pending application number is PCT/US12/67483. The title of invention is IMMUNOGENIC COMPOSITION COMPRISING PANTON-VALENTINE LEUKOCIDIN (PVL) DERIVED POLYPEPTIDES. There are no further patents, products in development or marketed products to declare. This does not alter the authors adherence to all the PLOS ONE policies on sharing data and materials, as detailed online in the guide for authors.","2013","06","Hatice Karauzum","HK",13,TRUE,5,9,5,4,TRUE,TRUE,FALSE,0,NA,FALSE
